ML901
ML901 is an antimalarial agent with an IC50 value of 2 nM against the malaria parasite. ML901 specifically inhibits the tyrosine tRNA synthetase of the malaria parasite (PfYRS) through "receptor hijacking". ML901 exhibits full life-cycle killing activity in the malaria mouse model. ML901 can be used for studying malaria parasite infection.
For research use only. We do not sell to patients.
- CAS No.: 2226228-02-8
- Formula: C11H14F2N6O7S
- Molecular Weight:412.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Parasite Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H1650 | EC50 |
10.02 μM
Compound: 4
|
Antiproliferative activity against human H1650 cells assessed as reduction in cell viability after 72 hrs by cell titer glow assay
Antiproliferative activity against human H1650 cells assessed as reduction in cell viability after 72 hrs by cell titer glow assay
|
[PMID: 32912429] |
Chemical Information
-
CAS No. 2226228-02-8
-
Molecular Weight 412.33
-
Formula C11H14F2N6O7S
-
SMILES
O[C@@H]1[C@H](O)[C@@H](COS(N)(=O)=O)O[C@H]1N2C3=NC=NC(N)=C3C(OC(F)F)=N2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)